KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Deferred Taxes: 2016-2025

Historic Deferred Taxes for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Sep 2025 value amounting to -$2.6 million.

  • Supernus Pharmaceuticals' Deferred Taxes rose 59.10% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.9 million, marking a year-over-year increase of 54.56%. This contributed to the annual value of -$20.1 million for FY2024, which is 21.69% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Deferred Taxes of -$2.6 million as of Q3 2025, which was up 63.07% from -$7.2 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Deferred Taxes peaked at $1.6 million during Q3 2021, and registered a low of -$13.0 million during Q1 2022.
  • Moreover, its 3-year median value for Deferred Taxes was -$5.6 million (2023), whereas its average is -$5.4 million.
  • In the last 5 years, Supernus Pharmaceuticals' Deferred Taxes spiked by 114.42% in 2021 and then crashed by 1,160.23% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Deferred Taxes stood at -$4.5 million in 2021, then tumbled by 71.87% to -$7.8 million in 2022, then tumbled by 34.78% to -$10.5 million in 2023, then spiked by 99.31% to -$72,000 in 2024, then surged by 59.10% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$7.2 million for Q2 2025, and -$4.0 million during Q1 2025.